Compare BioNano Genomics Inc (BNGO) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Microsoft — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Microsoft trades at $388.3 (market cap $2.86T). The key difference: Microsoft is far larger — about 216666.7× BioNano Genomics Inc's market cap, and Microsoft pays a 0.95% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | MSFT | |
|---|---|---|
Market Cap | $13.20M | $2.86T |
Sector | Health | Technology |
52-Week High | $4.92 | $542.07 |
52-Week Low | $1.09 | $352.83 |
Enterprise Value | $15.81M | $2.84T |
Volume | — | 36,654,621 |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Microsoft (MSFT) trades at $390.99, up 1.53% over 24 hours, with a neutral technical signal and strong fundamentals. The company reported Q1 2026 EPS of $4.27, beating expectations, and maintains robust profitability with a 39.34% net income margin. Revenue growth is steady, reaching $281.72B in 2025, supported by AI and cloud initiatives. Analyst consensus is overwhelmingly bullish with an 80.49% buy rating and a $552.81 price target.
Outlook remains positive due to AI leadership and consistent earnings beats, but risks include rising capital expenditures and competitive pressures. The stock offers growth potential with a reasonable P/E of 22.93, though investors should monitor execution on AI investments and macroeconomic headwinds that could impact tech valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
